^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | CKD-702 (c-MET inhibitor, EGFR antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract 3046: Anti-tumor efficacy of CKD-702 in EGFR TKI-resistant patient-derived xenograft model.
Published date:
05/15/2020
Excerpt:
We constructed the PDX model by transplanting surgical tissue from lung adenocarcinoma patient into NOD/SCID mice after the approval of research protocol in Seoul St. Mary's Hospital IRB....Our data showed that CKD-702 have effective anti-tumor activity in EGFR TKI-resistant PDX model harboring both activating EGFR mutation and c-MET overexpression.
DOI:
10.1158/1538-7445.AM2020-3046
